NOVARTIS (CAIN457F2206)

A randomized, double-blind, placebo-controlled regimen finding study of efficacy, safety and tolerability of secukinumab at 12 weeks administered i.v. compared to s.c. in patients with active rheumatoid arthritis despite treatment with methotrexate.